Bayer’s Eye Drug Shows Positive Results in Late-Stage Trial
Bayer said its eye treatment aflibercept showed positive results in a late-stage trial, including improved vision gains for people suffering from some retinal diseases.
GSK announces CHMP of the EMA recommended expanding approval of Jemperli
GSK (GSK) announced the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has recommended expanding the approval of Jemperli in combination with chemotherapy ...
GSK announces FDA granted BTD for Jemperli
GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for ...
Pharmabiz1 天
US FDA grants breakthrough therapy designation to GSK’s Jemperli for locally advanced ...
US FDA grants breakthrough therapy designation to GSK’s Jemperli for locally advanced dMMR/MSI-H rectal cancer: London, UK Tuesday, December 17, 2024, 09:00 Hrs [IST] GSK plc an ...
MARKET REPORT: Johnson Matthey rallies after shake-up demand
Standard Investments, which owns 11% of the FTSE 250 firm, urged the board to launch a strategic review to look at 'a sale of ...
Targeted Oncology2 天
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
The FDA granted breakthrough therapy designation to dostarlimab for locally advanced dMMR/MSI-H rectal cancer, highlighting ...
GSK的Jemperli获得CHMP对子宫内膜癌治疗的积极意见
在日本，GSK的呼吸道合胞病毒（RSV）疫苗Arexvy已获批用于50-59岁成年人。公司还报告了linerixibat的第三阶段GLISTEN试验的积极结果，该药物旨在治疗原发性胆汁性胆管炎患者的胆汁淤积性瘙痒。然而，由于预期2025年增长将趋于平缓，Jefferies和Guggenheim的金融分析师已下调了GSK的股票评级。
GSK的Jemperli获得FDA突破性疗法认定用于治疗直肠癌
Jemperli是一种抗PD-1抗体，是GSK免疫肿瘤学研究和开发的基础。它目前在美国获批用于某些类型的子宫内膜癌，并在加速批准下用于dMMR复发或晚期实体瘤，继续批准取决于确证性试验的验证。本报告基于GSK plc的新闻稿。
GSK’s Cancer Drug Jemperli Nears EU Marketing Expansion
In one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...
GSK's Cancer Drug Jemperli Nears EU Marketing Expansion -- 2nd Update
GSK's cancer drug Jemperli cleared an important hurdle ahead of potentially expanding its European Union marketing permission, in a boost to the pharmaceutical giant's oncology pipeline.
European Midday Briefing: Stocks Slip as Business Activity Slows Again
December's Composite Purchasing Managers' Index suggested firms in the currency area are cutting back on their payrolls for a fifth-straight month, a worrying sign for policymakers striving to avoid a ...